SparingVision is a clinical-stage biotechnology company developing mutation-independent genomic therapies for Inherited Retinal Diseases (IRDs), including Retinitis Pigmentosa, which affects millions globally. Their approach utilizes advanced gene therapy and genome editing techniques to provide treatment options for patients regardless of the specific genetic mutations causing their conditions.
Funding
$164.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JCUEFounders
Product
Problem
Inherited Retinal Diseases (IRDs), including Retinitis Pigmentosa, are a leading cause of blindness worldwide, affecting millions of individuals. Current treatment approaches often focus on single gene corrections, which are not applicable to all patients due to the high genetic heterogeneity of these diseases, with over 70 genes known to cause Retinitis Pigmentosa alone. This leaves a significant portion of the patient population without effective therapeutic options.
Solution
SparingVision is developing mutation-independent genomic medicines to treat Inherited Retinal Diseases (IRDs) like Retinitis Pigmentosa, addressing the limitations of single-gene correction therapies. Their approach uses gene therapy and genome editing techniques to deliver treatments that are effective regardless of the specific genetic mutation causing the disease. The lead product, SPVN06, is a gene therapy designed to target IRDs, offering a potential breakthrough for patients with limited or no existing treatment options. By moving beyond single gene correction, SparingVision aims to provide meaningful improvements for a broader range of patients affected by these blinding conditions.
Target Audience
The primary target audience includes individuals affected by Inherited Retinal Diseases (IRDs) such as Retinitis Pigmentosa, and the ophthalmologists and specialists who treat them.
Features
- Mutation-independent approach effective across various genetic causes of IRDs
- Utilizes gene therapy and genome editing technologies
- SPVN06: Lead product targeting IRDs